CN113144273A - Drive response composite material and preparation method and application thereof - Google Patents
Drive response composite material and preparation method and application thereof Download PDFInfo
- Publication number
- CN113144273A CN113144273A CN202110338133.XA CN202110338133A CN113144273A CN 113144273 A CN113144273 A CN 113144273A CN 202110338133 A CN202110338133 A CN 202110338133A CN 113144273 A CN113144273 A CN 113144273A
- Authority
- CN
- China
- Prior art keywords
- molecular polymer
- gel
- high molecular
- layer
- nanofiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002131 composite material Substances 0.000 title claims abstract description 60
- 230000004044 response Effects 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 82
- 239000002121 nanofiber Substances 0.000 claims abstract description 78
- 239000000126 substance Substances 0.000 claims abstract description 45
- 229920000642 polymer Polymers 0.000 claims abstract description 40
- 238000009987 spinning Methods 0.000 claims abstract description 39
- 239000000243 solution Substances 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 28
- 238000010041 electrostatic spinning Methods 0.000 claims abstract description 26
- 230000008569 process Effects 0.000 claims abstract description 20
- 239000011248 coating agent Substances 0.000 claims abstract description 19
- 238000000576 coating method Methods 0.000 claims abstract description 19
- 239000007864 aqueous solution Substances 0.000 claims abstract description 15
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 239000003431 cross linking reagent Substances 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 18
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 15
- 108010022355 Fibroins Proteins 0.000 claims description 14
- 238000004132 cross linking Methods 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 13
- 239000003102 growth factor Substances 0.000 claims description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 10
- 229920002674 hyaluronan Polymers 0.000 claims description 10
- 229960003160 hyaluronic acid Drugs 0.000 claims description 10
- -1 alginic acid polysaccharide Chemical class 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 9
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 239000000783 alginic acid Substances 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229960001126 alginic acid Drugs 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 7
- 229920001436 collagen Polymers 0.000 claims description 7
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 4
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 229940124350 antibacterial drug Drugs 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 239000003398 denaturant Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 46
- 208000027418 Wounds and injury Diseases 0.000 abstract description 46
- 239000012466 permeate Substances 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 4
- 230000029663 wound healing Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000000499 gel Substances 0.000 description 65
- 238000005507 spraying Methods 0.000 description 37
- 238000012360 testing method Methods 0.000 description 35
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 29
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 29
- 239000000835 fiber Substances 0.000 description 27
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- XDUXBBDRILEIEZ-UHFFFAOYSA-N 6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(CO)C3=CC=C2C2=C1C(C)=CO2 XDUXBBDRILEIEZ-UHFFFAOYSA-N 0.000 description 7
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 229920000747 poly(lactic acid) Polymers 0.000 description 5
- 239000004626 polylactic acid Substances 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- HYXITZLLTYIPOF-UHFFFAOYSA-N 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/62—Compostable, hydrosoluble or hydrodegradable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Botany (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention relates to a drive response composite material and a preparation method and application thereof, wherein the method comprises the steps of preparing spinning solution by taking a functional substance, a hydrophilic high molecular polymer I and a hydrophobic high molecular polymer as raw materials, preparing a nanofiber layer by adopting an electrostatic spinning process, and preparing a gel layer on one side of the nanofiber layer to obtain the drive response composite material; using the actuation responsive composite as a wound dressing, the gel layer directly contacting biological tissue; the functional substance can be driven and seeped into the gel layer to act on biological tissues under the applied condition; the functional material does not exude when no external condition is applied; and the single release amount of the functional substance in the wound dressing is less than 33.2 wt%. The method has simple process and wide application range; the wound dressing can be sprayed by an alcohol-containing aqueous solution according to requirements, so that functional substances firstly permeate into the gel coating and then reach biological tissues, and the wound dressing also has the antibacterial and anti-inflammatory effects while promoting wound healing.
Description
Technical Field
The invention belongs to the technical field of biomedical materials, and relates to a drive response composite material, and a preparation method and application thereof.
Background
A variety of wound dressings have been developed, including electrospun nanofiber membranes, hydrogels, and the like. In the dressings, the electrostatic spinning dressings can carry the medicine for slow release, and proper materials are selected to maintain certain mechanical property, so that the dressings cannot be damaged by external force in the using process. However, the drug loaded on the electrospun fiber is easy to cause burst release of the drug, and secondary loss is easy to cause when the wound is easy to adhere to the wound tissue and is replaced. Hydrogel dressings can maintain a moist wound environment to some extent, absorb tissue exudate, allow oxygen to permeate and cool the wound surface, and thereby relieve pain to the patient. But it is susceptible to some deformation or damage caused by external mechanical forces. The destruction shortens the life of the hydrogel, causing infection and further causing an inflammatory response.
The invention combines the characteristics of electrostatic spinning and hydrogel to develop a drive response composite material which has the function of controlling and releasing the drug as required, avoids the burst release of the drug, can promote the wound healing, has the functions of antibiosis, moisture preservation and ventilation, relieves the pain of patients and can maintain the excellent mechanical property.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a drive response composite material and a preparation method and application thereof. The invention can enable the wound dressing to have the effects of controllable and drug release according to requirements, has excellent antibacterial, anti-inflammatory and healing promotion functions, has excellent air permeability and moisture retention and can maintain the mechanical property of the dressing, reduce the replacement and use of the dressing and effectively solve the problems of the wound dressing.
In order to achieve the purpose, the invention adopts the following scheme:
a drive-responsive composite material characterized by: comprises a nanofiber layer and functional substances in the nanofiber layer;
the material of the nanofiber in the nanofiber layer is a mixed material of a hydrophilic high molecular polymer I and a hydrophobic high molecular polymer;
the functional substance can be driven under the applied external condition; the addition conditions were aqueous ethanol (75% ethanol).
As a preferred technical scheme:
in an actuated response composite as described above, the nanofibers in the nanofiber layer comprise hydrophilic high molecular polymer I nanofibers and hydrophobic high molecular polymer nanofibers.
A drive-responsive composite as described above, further comprising a gel layer bonded to said nanofiber layer; the main material of the gel layer is hydrophilic high molecular polymer II; the functional substance is capable of being driven into the gel layer under the application of an applied condition.
In a drive-responsive composite material as described above, the functional substance is dispersed in the form of fine particles (or powder) in the nanofibers.
The drive response composite material is characterized in that the functional substance is an extract of salvia miltiorrhiza, a monomer modifier of salvia miltiorrhiza, an antibacterial drug or a growth factor (the former three substances have antibacterial and anti-inflammatory effects, and the growth factor has a tissue repair promoting effect); the loading amount of the functional substance in the nanofiber layer is 0.3-29.7 ug/cm2。
The drive response composite material is prepared from PLGA, PGA, PLA or PLLA-CL (PLGA: polylactic acid-glycolic acid; PGA: polyglycolic acid; PLA: polylactic acid; PLLA-CL (block copolymer, copolymer of PLLA and PCL with the molar ratio of 1: 1) polylactic acid-caprolactone; PCL: polycaprolactone); the number average molecular weight Mn of the hydrophobic high molecular polymer is 8-15 ten thousand;
the hydrophilic high molecular polymer I is silk fibroin, collagen or collagen denaturant (such as gelatin);
the hydrophilic high molecular polymer II is hyaluronic acid or alginic acid polysaccharide; the number average molecular weight Mn of the hydrophilic high molecular polymer II is 20-100 ten thousand;
the mass ratio of the hydrophobic high-molecular polymer to the hydrophilic high-molecular polymer I is 0.8-1.2: 1.
The invention also provides a wound dressing made of a drive responsive composite material as described above, characterised in that: the gel layer directly contacts the biological tissue; the functional substance can be driven and seeped into the gel layer to act on biological tissues under the applied condition; the functional material does not exude when no external condition is applied; and the single release amount of the functional substance in the wound dressing is less than 33.2 wt%.
The invention also provides a preparation method of the drive response composite material, which is characterized in that a functional substance, a hydrophilic high molecular polymer I and a hydrophobic high molecular polymer are used as raw materials to prepare spinning solution, and an electrostatic spinning process is adopted to prepare the nanofiber layer.
The electrostatic spinning conditions can be as follows: the mass concentration (Mv) of the spinning solution is 4-20 percent; the spinning voltage is 10-30 kV, the spinning advancing speed is 0.5-2.5 mL/h, the receiving distance is 10-25 cm, and the receiver is conductive tinfoil paper. Wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cmX30 cm.
As a preferred technical scheme:
a method of making a drive-responsive composite as described above, a gel layer is formed on one side of the nanofiber layer.
The preparation method of the drive response composite material comprises the following steps:
(1) dissolving a hydrophilic high molecular polymer II in an aqueous solution containing methanol or ethanol, and adjusting to obtain a pre-gel;
(2) applying a pre-gel to a single-sided surface of the nanofiber layer; the coating thickness is 10-40 μm.
The preparation method of the drive response composite material comprises the following steps:
(1) dissolving a hydrophilic high molecular polymer II in an aqueous solution containing methanol or ethanol, and adjusting to obtain a pre-gel;
(2) adding a cross-linking agent, quickly stirring for 1-2 minutes, and immediately coating the pre-gel on the surface of one side of the nanofiber layer;
the coating thickness is 10-40 mu m, and the cross-linking agent is EDC/NHS or CaCl2The mass ratio of the cross-linking agent to the hydrophilic high molecular polymer II is 0.2-1: 1;
(3) standing at room temperature for crosslinking reaction, then ventilating and drying, and soaking the gel surface of the dried composite membrane into deionized water to remove the residues of the crosslinking agent and then drying;
the temperature of the crosslinking reaction is 4-20 ℃, and the crosslinking time is 2-4 hours.
The specific process of coating is as follows: and (2) pressing the polytetrafluoroethylene rectangular frame (with the size of 7cm, the length and the width of 15 cm) on the electrostatic spinning fiber membrane prepared in the step (1), quickly injecting 20mL of gel liquid and 1mL of cross-linking agent mixed solution into the mold frame to coat the fiber membrane, standing at 4-20 ℃ for cross-linking reaction for 2-4 hours, and then ventilating and drying at room temperature. And finally, immersing the gel surface of the composite membrane into deionized water for 6 hours to remove the residues of the cross-linking agent, sucking the surface moisture, and then placing the composite membrane in a vacuum drying oven to dry for 1 week at room temperature.
In the method for preparing the drive response composite material, the solvent of the spinning solution is hexafluoroisopropanol;
in the aqueous solution containing methanol or ethanol, the volume of the methanol or ethanol accounts for 5-10% of the total volume;
the mass content of the hydrophilic high molecular polymer II in the pre-gel is 1 to 5 percent;
the principle of the invention is as follows:
in the prior art, functional substances are embedded in gel and release drugs through gel degradation and other modes, the situation of drug burst release inevitably occurs, the release of the drugs is uninterrupted and cannot be forcibly stopped, the use period of validity is short when the drug is used as a wound dressing, and the utilization rate of the drugs is low; in the invention, the designed driving response composite material for the wound dressing is of a fiber and gel composite double-layer structure, and the gel layer directly contacting the tissue does not contain functional substances (in the preparation process, because the gel solution contains ethanol solution, a small amount of medicaments are enabled to be permeated into the gel layer closest to the fiber layer in a gradient manner, so that the aim of the driving response composite material is that the amount of the functional substances released in the first spraying is larger than the subsequent spraying release amount because the firstly required medicament amount of the damaged tissue is generally larger), and the fiber layer as the outer layer is formed by fibers of high molecular polymer loaded with the functional substances (namely, the fiber layer is a medicament reservoir); because the fibers in the fiber layer are mutually entangled, the fiber layer has better mechanical property, and the fibers in the fiber layer are a mixed material of hydrophilic high molecular polymer I and hydrophobic high molecular polymer, when the hydrophilic substance acts on the fiber layer, the functional substance is dissolved in the hydrophilic substance and permeates into the gel layer under the guiding action of the hydrophilic high molecular polymer I in the fiber layer, so that the transfer of the functional substance is more effective compared with the pure hydrophobic high molecular polymer fibers; compared with pure hydrophilic polymer fibers, the hydrophobic fibers can enable the fat-soluble medicine to be better dispersed in the fibers; further, when the solution formed by the functional substance enters the gel layer, the gel layer serves as a drug release passage, and since the permeation rate of the functional substance is related to the degree of crosslinking in the gel layer, the method of the present invention can reasonably design the degree of crosslinking in the gel layer according to the needs to adjust the permeation rate and dosage effect of the functional substance. The invention effectively controls the transfer of the functional substance by designing a unique fiber layer structure, controls the release of the functional substance by utilizing the structure of the gel layer and effectively avoids the burst release of the functional substance.
In addition, because the functional substance is positioned in the fiber layer and is continuously guided to the gel layer by applying external factors, the functional substance is dissolved by water or ethanol water solution and is guided to the gel layer; this "guided" actuation allows the release of the functional substance to be an external factor-responsive actuation rather than an uninterrupted or terminated actuation process, i.e.: when the external factor is present, the functional substance is driven into the gel layer, and when the external factor disappears, it is not driven. The controllable driving mode can avoid the burst release of the functional substances on one hand, and also control the release amount of the functional substances on the other hand, so that the utilization rate of the functional substances is improved, and the effective application time of the composite material is greatly prolonged.
Advantageous effects
(1) The preparation method of the drive response composite material is simple in process and wide in application range;
(2) according to the driving response composite material, functional substances can firstly permeate into the gel coating and then reach biological tissues by spraying the alcohol-containing aqueous solution according to needs, the wound healing is promoted, the antibacterial and anti-inflammatory effects are achieved, and the dressing does not need to be frequently replaced or even not replaced (the gel layer has a good moisturizing effect, the wound is not torn during replacement, and the anti-adhesion effect is achieved).
Drawings
FIG. 1 is a schematic diagram of the preparation and use of a drive-responsive composite material.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Further, it should be understood that various changes or modifications of the present invention may be made by those skilled in the art after reading the teaching of the present invention, and such equivalents may fall within the scope of the present invention as defined in the appended claims.
Example 1
A preparation method of a drive response composite material is shown in figure 1, and comprises the following specific steps:
(1) cryptotanshinone, silk fibroin with molecular weight of more than 14000 and PLGA with molecular weight of 10 ten thousand are taken as raw materials and added into hexafluoroisopropanol to prepare spinning solution with mass concentration (Mv) of 10 percent, and an electrostatic spinning process is adopted to prepare a nanofiber layer; wherein the content of cryptotanshinone in the spinning solution is 0.4 percent of the total mass of PLGA and silk fibroin; the mass ratio of PLGA to silk fibroin is 1: 1;
the conditions of electrostatic spinning are as follows: the spinning voltage is 18kV, the spinning advancing speed is 1.5mL/h, the receiving distance is 15cm, and the receiver is conductive tinfoil paper; wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cmx30 cm;
(2) dissolving hyaluronic acid with molecular weight of 40 ten thousand in an aqueous solution containing ethanol (the volume of the ethanol accounts for 10% of the total volume), and adjusting to obtain a pre-gel; wherein the mass content of hyaluronic acid in the pre-gel is 3%;
(3) and coating the pregel on the surface of one side of the nanofiber layer, wherein the thickness of the coating is 28 microns, and thus the driving response composite material is prepared.
The driving response composite material is used as a wound dressing and comprises a nanofiber layer and cryptotanshinone (the load is 6.6 ug/cm) dispersed in the nanofiber layer2) The gel layer is attached to the nanofiber layer; wherein the gel layer directly contacts with biological tissue, and cryptotanshinone can be driven and permeate into the gel layer under the action of ethanol water solution to act on biological tissue; the invention carries out cryptotanshinone driving test on the wound dressing, and the specific test process is as follows: spraying 500uL of 75% ethanol to one side of the nanofiber in the wound dressing in a spraying manner, and standing for 10min, and testing the release amount of cryptotanshinone driven for the first time; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, staying for 10min, and testing the release amount of cryptotanshinone driven for the second time; after 30min interval, spraying 500uL of 75% ethanol again to the same levelTesting the release amount of cryptotanshinone driven for the third time after the nano fiber side in the wound dressing stays for 10 min; the results of three tests are as follows:
example 2
A preparation method of a drive response composite material comprises the following specific steps:
(1) cryptotanshinone, silk fibroin with molecular weight of more than 14,000 and PLGA with molecular weight of 10 ten thousand are taken as raw materials and added into hexafluoroisopropanol to prepare spinning solution with mass concentration (Mv) of 10 percent, and an electrostatic spinning process is adopted to prepare a nanofiber layer, namely the driving response composite material;
wherein the content of cryptotanshinone in the spinning solution is 0.4 percent of the total mass of PLGA and silk fibroin; the mass ratio of PLGA to silk fibroin is 1: 1; the conditions of electrostatic spinning are as follows: the spinning voltage is 18kV, the spinning advancing speed is 1.5mL/h, the receiving distance is 15cm, and the receiver is conductive tinfoil paper; wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cmx30 cm;
the driving response composite material is used as a wound dressing and comprises a nanofiber layer and cryptotanshinone (the load is 6.9 ug/cm) dispersed in the nanofiber2) (ii) a And the cryptotanshinone can be driven to act on biological tissues; the wound dressing is subjected to cryptotanshinone driving test, and the specific test process comprises the following steps: spraying 500uL of 75% ethanol to one side of the nanofiber in the wound dressing in a spraying mode, and after staying for 10min, testing the release amount of the first drive; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, and after staying for 10min, testing the release amount of the second driving; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, and after staying for 10min, testing the release amount of the third driving; the results of three tests are given in the following table:
example 3
A preparation method of a drive response composite material comprises the following specific steps:
(1) adding cryptotanshinone, silk fibroin with the number average molecular weight Mn of more than 14,000 and PLGA with the number average molecular weight of 10 ten thousand serving as raw materials into hexafluoroisopropanol to prepare spinning solution with the mass concentration (Mv) of 10%, and preparing a nanofiber layer by adopting an electrostatic spinning process;
wherein the content of cryptotanshinone in the spinning solution is 0.4 percent of the total mass of PLGA and silk fibroin; the mass ratio of PLGA to silk fibroin is 1: 1; the conditions of electrostatic spinning are as follows: the spinning voltage is 18kV, the spinning advancing speed is 1.5mL/h, the receiving distance is 15cm, and the receiver is conductive tinfoil paper. Wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cmX30 cm.
(2) Dissolving hyaluronic acid with molecular weight of 40 ten thousand in an aqueous solution containing ethanol (the volume of the ethanol accounts for 10% of the total volume), and adjusting to obtain a pre-gel; wherein the mass content of hyaluronic acid in the pre-gel is 3%;
(3) adding a cross-linking agent, quickly stirring for 1-2 minutes, and immediately coating the pre-gel on the surface of one side of the nanofiber layer, wherein the thickness of the coating is 26 microns; the cross-linking agent is an EDC/NHS aqueous solution with the mass concentration of 20%, the mass ratio of EDC to NHS is 3:2, and the mass ratio of the cross-linking agent to hyaluronic acid is 1: 1;
(4) standing at 20 ℃, carrying out crosslinking reaction for 2 hours, then carrying out ventilation drying, immersing the gel surface of the dried composite membrane into deionized water to remove the residues of the crosslinking agent, and then drying to obtain the drive response composite material.
The driving response composite material is used as a wound dressing and comprises a nanofiber layer and cryptotanshinone (the load is 6.7 ug/cm) mainly dispersed in the nanofiber2) The gel layer is attached to the nanofiber layer; wherein the gel layer directly contacts with biological tissue, and cryptotanshinone can be driven and permeated into the gel layer under the action of ethanol water solution to act on biological groupWeaving; the invention carries out cryptotanshinone driving test on the wound dressing, and the specific test process is as follows: spraying 500uL of 75% ethanol to one side of the nanofiber in the wound dressing in a spraying manner, and standing for 10min, and testing the release amount of cryptotanshinone driven for the first time; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, staying for 10min, and testing the release amount of cryptotanshinone driven for the second time; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, staying for 10min, and testing the release amount of cryptotanshinone driven for the third time; the results of three tests are as follows:
example 4
A preparation method of a drive response composite material comprises the following specific steps:
(1) cryptotanshinone, silk fibroin with the number average molecular weight Mn of more than 14,000 and PLGA with the number average molecular weight of 10 ten thousand are taken as raw materials, added into hexafluoroisopropanol to prepare spinning solution with the mass concentration (Mv) of 12%, and an electrostatic spinning process is adopted to prepare a nanofiber layer;
wherein the content of cryptotanshinone in the spinning solution is 1.5 percent of the total mass of PLGA and silk fibroin; the mass ratio of PLGA to silk fibroin is 0.8: 1;
the conditions of electrostatic spinning are as follows: the spinning voltage is 12kV, the spinning advancing speed is 0.5mL/h, the receiving distance is 10cm, and the receiver is conductive tinfoil paper. Wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cmX30 cm.
(2) Dissolving hyaluronic acid with a molecular weight of 60 ten thousand in an aqueous solution containing ethanol (the volume of the ethanol accounts for 5% of the total volume), and adjusting to obtain a pre-gel; wherein the mass content of hyaluronic acid in the pre-gel is 1%;
(3) adding an EDC/NHS aqueous solution (a cross-linking agent and the mass ratio of EDC to NHS is 3:2) with the mass concentration of 10% into the pre-gel, quickly stirring for 1 minute, immediately coating the pre-gel on the single-side surface of the nanofiber layer, wherein the thickness of the coating is 14 mu m; the mass ratio of the cross-linking agent to the hyaluronic acid is 0.4: 1;
(4) standing at 4 ℃, carrying out crosslinking reaction for 4 hours, then carrying out ventilation drying, immersing the gel surface of the dried composite membrane into deionized water to remove the residues of the crosslinking agent, and then drying to obtain the drive response composite material.
The driving response composite material is used as a wound dressing and comprises a nanofiber layer and cryptotanshinone (the load is 29.7 ug/cm) mainly dispersed in the nanofiber2) The gel layer is attached to the nanofiber layer; wherein the gel layer directly contacts with biological tissue, and cryptotanshinone can be driven and permeated into the gel layer under the action of ethanol to act on the biological tissue; the invention carries out cryptotanshinone driving test on the wound dressing, and the specific test process is as follows: spraying 500uL of 75% ethanol to one side of the nanofiber in the wound dressing in a spraying manner, and standing for 10min, and testing the release amount of cryptotanshinone driven for the first time; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, staying for 10min, and testing the release amount of cryptotanshinone driven for the second time; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, staying for 10min, and testing the release amount of cryptotanshinone driven for the third time; the results of three tests are as follows:
example 5
A preparation method of a drive response composite material comprises the following specific steps:
(1) adding tanshinone II B, gelatin with number average molecular weight Mn of 80,000 and PLA with number average molecular weight of 10.5 ten thousand serving as raw materials into hexafluoroisopropanol to prepare spinning solution with mass concentration (Mv) of 15%, and preparing a nanofiber layer by adopting an electrostatic spinning process;
wherein the content of tanshinone II B in the spinning solution is 1 percent of the total mass of PLA and gelatin; the mass ratio of PLA to gelatin is 1.2: 1;
the conditions of electrostatic spinning are as follows: the spinning voltage is 30kV, the spinning advancing speed is 2.0mL/h, the receiving distance is 25cm, and the receiver is conductive tinfoil paper. Wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cmX30 cm.
(2) Dissolving alginic acid polysaccharide with molecular weight of 100 ten thousand in an aqueous solution containing ethanol (the volume of the ethanol accounts for 8% of the total volume), and adjusting to obtain a pre-gel; wherein the mass content of alginic acid polysaccharide in the pre-gel is 4%;
(3) adding a cross-linking agent, quickly stirring for 2 minutes, and immediately coating the pre-gel on the surface of one side of the nanofiber layer, wherein the thickness of the coating is 36 microns; the cross-linking agent is CaCl with the mass concentration of 15 percent2The mass ratio of the cross-linking agent to the alginic acid polysaccharide is 0.8: 1;
(4) standing at 20 ℃, carrying out crosslinking reaction for 2 hours, then carrying out ventilation drying, immersing the gel surface of the dried composite membrane into deionized water to remove the residues of the crosslinking agent, and then drying to obtain the drive response composite material.
The driving response composite material is used as a wound dressing and comprises a nanofiber layer, tanshinone II B (with the loading amount of 24.2 ug/cm) dispersed in the nanofiber in a particle form2) The gel layer is attached to the nanofiber layer; wherein the gel layer directly contacts with biological tissue, and tanshinone II B can be driven and permeated into the gel layer under the action of ethanol to act on the biological tissue; the driving test of the tanshinone II B is carried out on the wound dressing, and the specific test process comprises the following steps: spraying 500uL of 75% ethanol to one side of the nanofiber in the wound dressing in a spraying manner, and standing for 10min, and testing the release amount of the first-driven tanshinone II B; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, staying for 10min, and testing the release amount of the tanshinone II B driven for the second time; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing, standing for 10min, and testing for tanshinone II driven for the third timeThe amount of B released; the results of three tests are as follows:
example 6
A preparation method of a drive response composite material comprises the following specific steps:
(1) adding growth factor (VEGF), collagen with the number average molecular weight Mn of 100,000 and PLLA-CL (the molar ratio is 1: 1) with the number average molecular weight of 11 ten thousand serving as raw materials into hexafluoroisopropanol to prepare spinning solution with the mass concentration (Mv) of 10%, and preparing a nanofiber layer by adopting an electrostatic spinning process;
wherein, the content of the growth factor (VEGF) in the spinning solution is 0.02 percent of the total mass of the PLLA-CL and the collagen; the mass ratio of PLLA-CL to collagen is 0.9: 1; the conditions of electrostatic spinning are as follows: the spinning voltage is 20kV, the spinning advancing speed is 2mL/h, the receiving distance is 15cm, and the receiver is conductive tinfoil paper. Wherein, the size of the fiber membrane obtained by electrostatic spinning of every 10mL of spinning solution is 18cm x30 cm.
(2) Dissolving alginic acid polysaccharide with molecular weight of 80 ten thousand in aqueous solution containing methanol (the volume of the methanol accounts for 8% of the total volume), and adjusting to obtain pre-gel; wherein the mass content of alginic acid polysaccharide in the pre-gel is 2%;
(3) adding a cross-linking agent, quickly stirring for 1 minute, and immediately coating the pre-gel on the surface of one side of the nanofiber layer, wherein the thickness of the coating is 23 mu m; the cross-linking agent is CaCl with the mass concentration of 10 percent2The mass ratio of the cross-linking agent to the alginic acid polysaccharide is 0.4: 1;
(4) standing at 10 ℃, carrying out crosslinking reaction for 3 hours, then carrying out ventilation drying, immersing the gel surface of the dried composite membrane into deionized water to remove the residues of the crosslinking agent, and then drying to obtain the drive response composite material.
The driving response composite material is used as a wound dressing and comprises a nanofiber layer, and growth factors (VEGF) (the loading amount is 0.3 ug/cm) mainly dispersed in the nanofibers2) Gel layer laminated with nanofiber layer(ii) a Wherein the gel layer is in direct contact with the biological tissue, and the growth factor (VEGF) can be driven and infiltrated into the gel layer under the action of ethanol to act on the biological tissue; the wound dressing is subjected to a driving test of a growth factor (VEGF), and the specific test process comprises the following steps: spraying 500uL of 75% ethanol to one side of the nanofiber in the wound dressing in a spraying mode, and testing the release amount of a growth factor (VEGF) driven for the first time after staying for 10 min; after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, and after staying for 10min, testing the release amount of a second-time driven growth factor (VEGF); after 30min, spraying 500uL of 75% ethanol to one side of the nanofiber in the same wound dressing in a spraying mode again, and after staying for 10min, testing the release amount of growth factor (VEGF) driven for the third time; the results of three tests are as follows:
Claims (10)
1. a drive-responsive composite material characterized by: comprises a nanofiber layer and functional substances in the nanofiber layer; the material of the nanofiber in the nanofiber layer is a mixed material of a hydrophilic high molecular polymer I and a hydrophobic high molecular polymer;
the functional substance can be driven under the applied external condition; the additional condition is ethanol water solution.
2. The drive-response composite of claim 1, wherein the nanofibers in the nanofiber layer comprise hydrophilic high molecular polymer I nanofibers and hydrophobic high molecular polymer nanofibers;
the drive-responsive composite further comprises a gel layer bonded to the nanofiber layer; the main material of the gel layer is hydrophilic high molecular polymer II; the functional substance is capable of being driven into the gel layer under the application of an applied condition.
3. A drive-responsive composite as claimed in claim 1 or claim 2 wherein the functional material is dispersed predominantly in the nanofibres;
the functional substance is an extract of salvia miltiorrhiza, a monomer modifier of salvia miltiorrhiza, an antibacterial drug or a growth factor; the loading amount of the functional substance in the nanofiber layer is 0.3-29.7 ug/cm2。
4. A drive-responsive composite according to claim 1 or 2 wherein the hydrophobic polymer is PLGA, PGA, PLA or PLLA-CL; the number average molecular weight Mn of the hydrophobic high molecular polymer is 8-15 ten thousand;
the hydrophilic high molecular polymer I is silk fibroin, collagen or a collagen denaturant;
the hydrophilic high molecular polymer II is hyaluronic acid or alginic acid polysaccharide; the number average molecular weight Mn of the hydrophilic high molecular polymer II is 20-100 ten thousand;
the mass ratio of the hydrophobic high-molecular polymer to the hydrophilic high-molecular polymer I is 0.8-1.2: 1.
5. A wound dressing made from a drive responsive composite material as claimed in any one of claims 2 to 4, wherein: the gel layer directly contacts the biological tissue; the functional substance can be driven and seeped into the gel layer to act on biological tissues under the applied external condition, the functional substance does not seep out under the non-applied external condition, and the single release amount of the functional substance in the wound dressing is less than 33.2 wt%.
6. A method of making a drive-responsive composite as claimed in any one of claims 1 to 4, wherein: preparing spinning solution by taking a functional substance, a hydrophilic high molecular polymer I and a hydrophobic high molecular polymer as raw materials, and preparing the nanofiber layer by adopting an electrostatic spinning process.
7. The method of claim 6, wherein a gel layer is formed on one side of the nanofiber layer.
8. The method of claim 7, wherein the step of preparing the gel layer comprises:
(1) dissolving a hydrophilic high molecular polymer II in an aqueous solution containing methanol or ethanol, and adjusting to obtain a pre-gel;
(2) applying a pre-gel to a single-sided surface of the nanofiber layer; the coating thickness is 10-40 μm.
9. The method of claim 7, wherein the step of preparing the gel layer comprises:
(1) dissolving a hydrophilic high molecular polymer II in an aqueous solution containing methanol or ethanol, and adjusting to obtain a pre-gel;
(2) adding a cross-linking agent, quickly stirring for 1-2 minutes, and immediately coating the pre-gel on the surface of one side of the nanofiber layer;
the coating thickness is 10-40 mu m, and the cross-linking agent is EDC/NHS or CaCl2The mass ratio of the cross-linking agent to the hydrophilic high molecular polymer II is 0.2-1: 1;
(3) standing for crosslinking reaction, then ventilating and drying, and immersing the gel surface of the dried composite membrane into deionized water to remove the residues of the crosslinking agent and then drying;
the temperature of the crosslinking reaction is 4-20 ℃, and the crosslinking time is 2-4 hours.
10. The method of claim 8 or 9, wherein the solvent of the spinning solution is hexafluoroisopropanol;
in the aqueous solution containing methanol or ethanol, the volume of the methanol or ethanol accounts for 5-10% of the total volume;
the mass content of the hydrophilic high molecular polymer II in the pre-gel is 1-5%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110338133.XA CN113144273B (en) | 2021-03-30 | 2021-03-30 | Drive response composite material and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110338133.XA CN113144273B (en) | 2021-03-30 | 2021-03-30 | Drive response composite material and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113144273A true CN113144273A (en) | 2021-07-23 |
| CN113144273B CN113144273B (en) | 2022-08-26 |
Family
ID=76885245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110338133.XA Active CN113144273B (en) | 2021-03-30 | 2021-03-30 | Drive response composite material and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113144273B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028603A (en) * | 2021-11-02 | 2022-02-11 | 太原理工大学 | Double-layer asymmetric dressing for promoting skin wound repair and preparation method thereof |
| CN116876108A (en) * | 2023-07-07 | 2023-10-13 | 江西省纳米技术研究院 | Multifunctional coaxial composite fiber, its preparation method and application |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102600018A (en) * | 2012-03-31 | 2012-07-25 | 华南理工大学 | Medical dressing with cooling function and wound healing prompting function and preparation method of medical dressing |
| US20130150763A1 (en) * | 2011-12-07 | 2013-06-13 | Esmaeil Mirzaei | Electro spun nanofibrous wound dressing and a method of synthesizing the same |
| CN103751851A (en) * | 2014-01-17 | 2014-04-30 | 东华大学 | Preparation method of inorganic/organic multi-drug controlled release composite nano fiber scaffold |
| WO2014182536A1 (en) * | 2013-05-10 | 2014-11-13 | Biovation Ii, Llc | Biopolymer multi-layer multi-functional medical dressing and method of making same |
| CN104491914A (en) * | 2014-12-25 | 2015-04-08 | 中国人民解放军第四军医大学 | Porous complex gel-nanofiber oxygen permeation dressing and preparation method thereof |
| KR20150084519A (en) * | 2014-01-14 | 2015-07-22 | 연세대학교 산학협력단 | Multi-layered electrospun fiber incorporated hydrogel |
| CN106676753A (en) * | 2016-12-28 | 2017-05-17 | 嘉兴学院 | Antibacterial nano fiber and preparation method thereof |
| CN107519524A (en) * | 2017-09-21 | 2017-12-29 | 滨州医学院 | A kind of polycaprolactone/collagen/quaternary ammonium salt electrospun composite fibers film and preparation method thereof |
| CN108042838A (en) * | 2017-12-20 | 2018-05-18 | 华中科技大学同济医学院附属协和医院 | A kind of preparation method of anti-oxidative nanofiber electrospinning film medical dressing |
| CN109529123A (en) * | 2018-11-08 | 2019-03-29 | 中国人民解放军第四军医大学 | The vascularization holostrome organization engineering skin and preparation method thereof that hydrogel, nano fiber scaffold and Skin Cell assemble layer by layer |
| KR20190060326A (en) * | 2017-11-24 | 2019-06-03 | 연세대학교 산학협력단 | Multifunctional nanofiber scaffolds and preparation method thereof |
| CN110876711A (en) * | 2019-12-11 | 2020-03-13 | 北京化工大学 | A kind of method for preparing multilayer polymer microneedle |
| CN111001028A (en) * | 2019-12-29 | 2020-04-14 | 北京工商大学 | Methylene blue antioxidant repair polymer nanofiber membrane and preparation method thereof |
-
2021
- 2021-03-30 CN CN202110338133.XA patent/CN113144273B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130150763A1 (en) * | 2011-12-07 | 2013-06-13 | Esmaeil Mirzaei | Electro spun nanofibrous wound dressing and a method of synthesizing the same |
| CN102600018A (en) * | 2012-03-31 | 2012-07-25 | 华南理工大学 | Medical dressing with cooling function and wound healing prompting function and preparation method of medical dressing |
| WO2014182536A1 (en) * | 2013-05-10 | 2014-11-13 | Biovation Ii, Llc | Biopolymer multi-layer multi-functional medical dressing and method of making same |
| KR20150084519A (en) * | 2014-01-14 | 2015-07-22 | 연세대학교 산학협력단 | Multi-layered electrospun fiber incorporated hydrogel |
| CN103751851A (en) * | 2014-01-17 | 2014-04-30 | 东华大学 | Preparation method of inorganic/organic multi-drug controlled release composite nano fiber scaffold |
| CN104491914A (en) * | 2014-12-25 | 2015-04-08 | 中国人民解放军第四军医大学 | Porous complex gel-nanofiber oxygen permeation dressing and preparation method thereof |
| CN106676753A (en) * | 2016-12-28 | 2017-05-17 | 嘉兴学院 | Antibacterial nano fiber and preparation method thereof |
| CN107519524A (en) * | 2017-09-21 | 2017-12-29 | 滨州医学院 | A kind of polycaprolactone/collagen/quaternary ammonium salt electrospun composite fibers film and preparation method thereof |
| KR20190060326A (en) * | 2017-11-24 | 2019-06-03 | 연세대학교 산학협력단 | Multifunctional nanofiber scaffolds and preparation method thereof |
| CN108042838A (en) * | 2017-12-20 | 2018-05-18 | 华中科技大学同济医学院附属协和医院 | A kind of preparation method of anti-oxidative nanofiber electrospinning film medical dressing |
| CN109529123A (en) * | 2018-11-08 | 2019-03-29 | 中国人民解放军第四军医大学 | The vascularization holostrome organization engineering skin and preparation method thereof that hydrogel, nano fiber scaffold and Skin Cell assemble layer by layer |
| CN110876711A (en) * | 2019-12-11 | 2020-03-13 | 北京化工大学 | A kind of method for preparing multilayer polymer microneedle |
| CN111001028A (en) * | 2019-12-29 | 2020-04-14 | 北京工商大学 | Methylene blue antioxidant repair polymer nanofiber membrane and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| ASGHAR ESKANDARINIA等: "A novel Bilayer Wound Dressing composed of a Dense polyurethane/propolis Membrane and a Biodegradable polycaprolactone/Gelatin Nanofbrous Scafold", 《SCIENTIFIC REPORTS》 * |
| CHENG-HUNG LEE等: "Nanofibrous rhPDGF-eluting PLGA–collagen hybrid scaffolds enhance healing of diabetic wounds", 《RSC ADV.》 * |
| YUAN LIAN等: "Fabrication and characterization of curcumin-loaded silk fibroin/P(LLA-CL) nanofibrous scaffold", 《FRONT. MATER. SCI.》 * |
| 石锐等: "PCL基电纺纤维膜的抑菌、相容及降解性能研究", 《生物骨科材料与临床研究》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114028603A (en) * | 2021-11-02 | 2022-02-11 | 太原理工大学 | Double-layer asymmetric dressing for promoting skin wound repair and preparation method thereof |
| CN116876108A (en) * | 2023-07-07 | 2023-10-13 | 江西省纳米技术研究院 | Multifunctional coaxial composite fiber, its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113144273B (en) | 2022-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Heydari et al. | Preparation and evaluation of poly glycerol sebacate/poly hydroxy butyrate core‐shell electrospun nanofibers with sequentially release of ciprofloxacin and simvastatin in wound dressings | |
| CN102068339B (en) | Preparation method of biodegradable nanofiber medical dressing loaded with medicine | |
| CN100577720C (en) | Biodegradable and absorbable polymer nanofiber membrane material and its preparation method and use | |
| CN103394114B (en) | A kind of preparation method of medical dressing chitosan-based superfine fiber carrier material | |
| CN111588900B (en) | Waterproof, breathable, high-elasticity, self-repairing double-layer nanofiber membrane for skin dressing and its preparation method | |
| CN1961974B (en) | Biodegradable and absorbable polymer nanofiber membrane material and its preparation method and use | |
| Nur et al. | Recent advances in bioactive wound dressings | |
| CN103611182A (en) | Preparation method of core-shell structure superfine fiber carrier material for medical dressing | |
| Zhang et al. | Recent progress of electrospun nanofibers as burning dressings | |
| CN102266582A (en) | Preparation method for drug-loaded nanometer fiber medical dressing | |
| EP3658197B1 (en) | Electrospun nanofibers and membrane | |
| KR20140090704A (en) | Artificial dura mater and manufacturing method thereof | |
| CN103933602A (en) | Preparation method of chitosan-based drug-loading composite antibacterial superfine fiber membrane | |
| Coelho et al. | Electrospinning technology: designing nanofibers toward wound healing application | |
| WO2020186715A1 (en) | Drug-loaded nanofiber film and preparation method and application thereof | |
| Abdelhakeem et al. | State-of-the-art review of advanced electrospun nanofiber composites for enhanced wound healing | |
| CN113144273A (en) | Drive response composite material and preparation method and application thereof | |
| Tamilarasi et al. | Electrospun scaffold-based antibiotic therapeutics for chronic wound recovery | |
| Wu et al. | Electrospun nanofiber scaffold for skin tissue engineering: a review | |
| CN115058892A (en) | A kind of lactic acid porous fiber membrane and its application | |
| Plascencia Martinez et al. | Comparative study of single and coaxial electrospun antimicrobial cross-linked scaffolds enriched with Aloe Vera: Characterization, antimicrobial activity, drug delivery, cytotoxicity, and cell proliferation on adipose stem cells and human skin fibroblast | |
| Rajchal et al. | Insights into electrospun polymeric nanofiber mats: an innovative dressing for wound healing applications | |
| CN117860945A (en) | Sandwich-like structure drug-carrying micro-nano fiber composite film medical dressing and preparation method thereof | |
| CN103263381B (en) | Fiber type controllable drug sustained release system and preparation method thereof | |
| CN112353780A (en) | Drug sustained and controlled release platform system with double nano composite structures |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yin Anlin Inventor after: Sun Wenling Inventor after: Zhang Kuihua Inventor after: Li Zhe Inventor after: Li Yunhuan Inventor after: Fan Yongyong Inventor before: Yin Anlin Inventor before: Zhang Kuihua Inventor before: Li Zhe Inventor before: Li Yunhuan Inventor before: Fan Yongyong |
|
| CB03 | Change of inventor or designer information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 314000 No. 899, guangqiong Road, Nanhu District, Jiaxing City, Zhejiang Province Patentee after: Jiaxing University Country or region after: China Address before: No. 899 Guangqiong Road, Nanhu District, Jiaxing City, Zhejiang Province Patentee before: JIAXING University Country or region before: China |
|
| CP03 | Change of name, title or address |